Routine Testing for Chlamydia and Gonorrhea in an HIV Pre-Exposure Prophylaxis Program in Hanoi, Vietnam: Implications for Low- and Middle-Income Countries

Paul C. ADAMSON[1], Hao T.M. BUI[2], Loc Q. PHAM[2], Phuong T. TRUONG[3], Ngan T. LE[3], Giang M. LE*[2], Jeffrey D. KLAUSNER*[4]

Author Affiliations: [1] Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, USA; [2] Center for Training and Research on Substance Abuse and HIV, Hanoi Medical University, Hanoi, Vietnam; [3] Department of Microbiology, Bach Mai Hospital, Hanoi, Vietnam;[4] Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, USA. *LMG and JDK are joint senior authors.

Corresponding Author: Paul Adamson MD MPH, Division of Infectious Diseases, School of Medicine, University of California, Los Angeles, 911 Broxton Ave, Suite 301, Los Angeles, CA, USA, 90024, Phone: (310) 794-5865; Email: PAdamson@mednet.ucla.edu

Conflicts of Interest and Funding: This work was supported by the US National Institute of Allergy and Infectious Diseases (R21 AI157817 to G. M. L and J. D. K.) and the Fogarty International Center (K01TW012170 to P. C. A). The funders had no role in the data collection, analysis, manuscript preparation, or decision to publish. JDK reports consulting fees from Abbott in the prior 12 months. All other authors report no potential conflicts of interest.

Publication history: This manuscript was previously posted to medRxiv: doi:

https://doi.org/10.1101/2024.08.30.24312811

Word Count: 3,390; References: 29; Tables – 3; Figures – 1

Short Title: CT/NG Testing in an HIV PrEP Program in Vietnam

Abstract

Objectives: To assess the prevalence, anatomical distribution, and correlates of *Neisseria gonorrhoeae* (NG) and *Chlamydia trachomatis* (CT) infections within an HIV pre-exposure prophylaxis (PrEP) program in Hanoi, Vietnam.

Design: Cross-sectional, observational study

Methods: Between January-December 2022, HIV PrEP program clients who were male at birth, ≥16 years old, reported ≥1 male sex partner in the prior 12 months, were enrolled. A questionnaire collected sociodemographics, sexual behaviors, and clinical data. CT/NG testing was performed on self-collected urine, rectal, and pharyngeal specimens. Multivariate logistic regression was used to identify factors associated with infections.

Results: Among 529 participants, the prevalence of CT or NG was 28.9% (153/529). The prevalence of NG was 14.4% (76/529) and highest for pharyngeal infections (11.7%; 62/528), while for CT, the prevalence was 20.4% (108/529) and highest for rectal infections (15.0%; 74/493). Symptoms in the prior week were reported by 45.8% (70/153) of those with CT or NG infections. Among asymptomatic participants, there was a low prevalence of urethral CT (3.1%; 14/457) and NG (0.9%; 4/457). Condomless anal sex (aOR= 1.98; 95% CI: 1.27, 3.09) and sexualized drug use in the prior 6 months (aOR= 1.71; 95% CI: 1.09, 2.69) were associated with CT/NG infections.

Conclusions: The study found a high prevalence of CT/NG infections, particularly pharyngeal and rectal infections, within an HIV PrEP program in Hanoi, Vietnam. The findings suggest testing for urethral infections among asymptomatic individuals is of limited value. Further

research is needed for STI prevention strategies and updated guidelines for CT/NG screening in HIV PrEP programs in low- and middle-income countries.

Keywords: Neisseria gonorrhoeae, Chlamydia trachomatis, HIV Pre-Exposure Prophylaxis, Sexually Transmitted Infections, Low- and Middle-Income Countries, Men who have sex with men

53 **Introduction**

54 Sexually transmitted infections (STIs) are a significant public health challenge globally. *Neisseria*
55 *gonorrhoeae* and *Chlamydia trachomatis* are the two most common bacterial STIs. Men who
56 have sex with men (MSM) are disproportionately affected by STIs.[1,2] MSM on HIV pre-
57 exposure prophylaxis (PrEP) have high frequencies of bacterial STIs. [3–5] Thus, major HIV PrEP
58 guideline groups recommend routine screening for *C. trachomatis* and *N. gonorrhoeae* among
59 MSM on HIV PrEP, including testing at multiple anatomic sites of infection.

60

61 In low- and middle-income countries (LMICs), HIV PrEP programs are expanding, yet data on
62 STIs among MSM in HIV PrEP programs are limited. Understanding the epidemiology of STIs in
63 these settings is important for planning and implementation of HIV PrEP programs. Moreover,
64 in many LMIC settings, the availability of molecular *C. trachomatis* and *N. gonorrhoeae* testing is
65 limited and the costs associated testing remain significant barriers for testing.[6,7] Identifying
66 clinical and behavioral risk factors associated with those infections can help optimize diagnosis
67 and prevention of STIs, particularly in LMIC settings where resources might be limited and there
68 is ongoing rapid scale-up of HIV PrEP services.

69

70 Vietnam is a LMIC where HIV PrEP became available in 2018. Prior to that, baseline data from
71 the Hanoi-MSM (HIM) study found a high prevalence of *C. trachomatis* (22%) and *N.*
72 *gonorrhoeae* (12%) among MSM without HIV, who subsequently were enrolled into the pilot
73 HIV PrEP project.[8] Currently, HIV PrEP guidelines in Vietnam recommend quarterly screening
74 for *C. trachomatis* and *N. gonorrhoeae* at all sites with potential exposure[9]; however, the

clients are responsible for covering the majority of the costs of those tests, which greatly limits testing uptake and available data on infections. The aims of this study are to fill gaps in research on STIs among MSM on HIV PrEP in Vietnam, since the rollout of HIV PrEP. The study objectives were to determine the prevalence of urethral, rectal, and pharyngeal *N. gonorrhoeae* and *C. trachomatis* infections within an HIV PrEP program in Hanoi, Vietnam, as well as to determine behavioral and clinical factors associated with *N. gonorrhoeae* and *C. trachomatis* infections.

Methods:

Study design and population

This was an observational, cross-sectional study from January 2022 to December 2022. The study was conducted within the HIV PrEP program at the Sexual Health and Promotion (SHP) Clinic at Hanoi Medical University. Study participants were eligible if they were male sex at birth, aged 16 years or older, reported having sex with men or transgender women in prior 12 months, and were enrolled in, or presenting for enrollment into, the HIV PrEP program; exclusion criteria were if they had *C. trachomatis* or *N. gonorrhoeae* testing done in the prior 3 months, unless they reported acute STI symptoms on the day of enrollment. The exclusion criteria were included to align closely with the HIV PrEP program recommendations. Participants were allowed to participate in the study more than once. Eligible participants were approached in the clinic and the study's objectives and procedures were explained by study research staff.

Data collection

Demographic, behavioral, and clinical characteristics were collected using a tablet self-administered survey. Sexual behaviors were self-reported and included: number of sex partners in the prior month as the combined number of male, female, and transgender sex partners, anal

sex position(s), condomless anal intercourse in the prior month, group sex (defined as having more than one sex partner at the same encounter), or having sex with partners met via mobile apps in the prior 6 months. Sexualized drug use was considered if the participant reported using a substance (heroine, ketamine, ecstasy, methamphetamine, gamma hydroxybutyrate or gamma butyrolactone, poppers, or prostaglandin E medications) in the prior 6 months to enhance sexual pleasure. Poppers are commonly included in the definition of sexualized drug use in the Asia Pacific region.[10] History of STIs in the prior three months was obtained by self-report.

Participants were asked about any genitourinary, rectal, or pharyngeal symptoms in the prior one week. Genitourinary symptoms were classified as any of the following: pain with urination, discharge, bleeding, pruritis, testicular pain, lymphadenopathy, or ulcers. Rectal symptoms were classified as any of the following: tenesmus, dyschezia, pruritis, bleeding, discharge, ulcers, or diarrhea. Pharyngeal symptoms included pain or itching in the throat.

Sample collection, testing, and treatment

Study participants received instructions on providing rectal, pharyngeal, and urine specimens for testing by study staff and with visual aids. Clinician-collected samples were obtained if participants preferred or were unable to perform self-collection. Study specimens were collected using either the Alinity m multi-Collect Specimen Collection Kits (Abbott Molecular, USA) or cobas PCR Urine or Swab Sample Kits (Roche Diagnostics, Branchburg, NJ, USA). Specimens were stored in the clinic and transported daily to the laboratory. Testing was performed using either the Alinity m STI Assay (Abbott Molecular, USA) or the cobas 4800 CT/NG assay (Roche Diagnostics, Branchburg, NJ, USA) according to manufacturer's instructions. Test results for *C. trachomatis* and *N. gonorrhoeae* were either positive, negative, or inconclusive, in the event of failed internal controls or the presence of inhibitors. Participants

were informed of their test results. For those found to have infections, free treatment was offered. For *C. trachomatis* infections, doxycycline 100mg by mouth twice daily for 7 days was provided. For *N. gonorrhoeae* infections, ceftriaxone 500mg intramuscular injection once was the preferred treatment offered; cefixime 800mg by mouth once was provided as an alternative treatment.

Data analysis

The primary outcome was the prevalence of *C. trachomatis* or *N. gonorrhoeae* infections at different anatomic sites. The study sample size was determined based on available resources, staffing, and a defined study duration (2022). Rather than relying on formal sample size calculations, recruitment was intentionally inclusive of all eligible study participants, that could be enrolled based on research timing and staffing. A sample size of 500 would have a reasonable estimate of infection prevalence with a margin of error <5%. Descriptive statistics were performed for demographic, behavioral and clinical data; percentages for categorical variables, or median and interquartile range for continuous variables, were reported. Categorical variables between those with and without *C. trachomatis* or *N. gonorrhoeae* infections were compared using Pearson's Chi-squared test and Fisher's exact test, when frequencies were low, and nonparametric continuous variables were compared using Wilcoxon rank-sum tests.

Logistic regression modeling was used to evaluate factors associated with *N. gonorrhoeae* and *C. trachomatis* infections separately as well as the outcome of having either infection. Variables with p-values < 0.20 in univariate comparisons were included in the multivariable logistic regression models; except for age, which was included in the final models. The number of sex partners in the prior month was dichotomized to above or below the median (0-1 and ≥2) to improve interpretation and model fit. For participants with multiple study visits, data analysis was restricted to their first participation. A variance inflation factor was used to measure for

multicollinearity between variables in the multivariate logistic regression. Variables with missing data were excluded from the logistic regression models. P-values ≤ 0.05 was defined as statistical significance. All data analyses were performed using STATA version 18 (StataCorp LLC, College Station, TX, USA).

Ethics

The study was approved by the Institutional Review Boards of Hanoi Medical University (HMUIRB580), the University of California, Los Angeles, and the University of Southern California. All study participants provided written informed consent. People aged 16 years or older are eligible for the HIV PrEP program, thus study eligibility included these individuals, who could participate in the study with assent and parental consent. Participants were compensated 200,000 VND (~9 USD) for their time and effort of study participation.

Results

Participant Characteristics

From January to December 2022, there were 529 participants enrolled into the study among 775 approached and 538 screened. The primary reasons for refusal of those who were approached, but who did not undergo screening, was “too busy/not enough time” or “will consider next time.” Multiple visits occurred for 134 participants: 116 with two, 16 with three, and two with four visits. Among the study participants, 81.6% (432/529) identified as a man, 1.7% (9/529) identified as transgender woman, and 16.6% (88/529) identified as gender non-conforming. (Table 1). The median age among all participants was 25.1 years (IQR: 21.7-29.5). There were 29.1% (154/529) currently undergoing university or post-secondary training, while 61.1% (323/529) had completed university or post-secondary training.

In the prior six months, 95.8% (507/529) reported only male sex partners; the median number of sex partners in the prior month was 1 (IQR: 1-2). (Table 1). Anal sex in the prior 6 months was reported by 88.4% (396/529), of which 51.2% reported condomless anal sex in the prior month. In the prior 6 months, group sex was reported by 12.3% (65/529) and sexualized substance use was reported by 45.4% (240/529). A history of a STI in the prior 3 months was reported by 5.5% (29/529), with 69.0% (20/29) of those being syphilis. Additional sexual behavior data are shown in Table 1.

C. trachomatis and N. gonorrhoeae infections

All participants submitted a urine sample for testing, a pharyngeal specimen was not collected for one (0.2%) participant, while 11 (2.1%) participants refused rectal specimen collection. In total, 28.9 % (153/529) participants had *C. trachomatis* or *N. gonorrhoeae* infections at any anatomical site. The prevalence of C. *trachomatis* was 20.4% (108/529) and 14.3% (76/529) for *N. gonorrhoeae*; 5.9% (31/529) of participants had *C. trachomatis* and *N. gonorrhoeae* co-infections (Table 1). Among the 153 participants with either *C. trachomatis* or *N. gonorrhoeae* infections, the median age was 25.1 years (IQR: 21.5 – 28.3). The median number of sex partners in the prior month was 2 (IQR: 1-3), 14.2% (22/155) reported group sex in the prior month, and 60.1% (94/155) reported sexualized substance use. Of the 153 with *C. trachomatis* or *N. gonorrhoeae* infections, 45.8% (70/153) reported any symptoms in the prior week; 33 (21.6%) reported pharyngeal symptoms, 29 (19.0%) reported rectal symptoms, and 26 (17.0%) reported urethral symptoms. More participants with *C. trachomatis* or *N. gonorrhoeae*

198 infections reported having symptoms on the day of enrollment, compared to those without
199 infections (9.2% vs. 3.0%, p=0.001).
200
201 *C. trachomatis* and *N. gonorrhoeae* infections by anatomic site are shown in Table 2. The
202 prevalence of *C. trachomatis* was highest in the rectum (15.0%; 74/493) and 3.4% (18/529) had
203 infections in multiple anatomic sites. For *N. gonorrhoeae*, pharyngeal site infections were most
204 prevalent (11.7%; 62/528) and 6.0% (32/529) had infections at multiple anatomic sites. Among
205 participants with either *C. trachomatis* or *N. gonorrhoeae*, the prevalence of rectal infections
206 was 19.1% (94/493) and 9.3% (49/529) had infections at multiple anatomic sites. For rectal
207 specimens, 24 (4.5%) were inconclusive for both infections and one additional result was
208 inconclusive for *C. trachomatis*.
209
210 The prevalence of *C. trachomatis* or *N. gonorrhoeae* infections by anatomic site, stratified by
211 reported symptoms in the prior week are shown in Figure 1. Among those reporting rectal
212 symptoms in the prior week, the prevalence of having a rectal infection with *C. trachomatis* or
213 *N. gonorrhoeae* was 27.2% (22/81), followed by 25.0% (18/72) for urethral symptoms and
214 urethral infections, and 18.3% (23/126) for pharyngeal symptoms and pharyngeal infections.
215 Among those who did not report symptoms in the prior week, the prevalence of urethral *C.*
216 *trachomatis* was 3.1% (14/457) and 0.9% (4/457) for *N. gonorrhoeae*. For both infections, the
217 prevalence of both rectal and urethral infections were higher among those reporting symptoms
218 in the prior week; there were no differences in the prevalence of pharyngeal infections by
219 symptom status for either infection.

220

221 *Factors associated with* C. *trachomatis and N. gonorrhoeae infections*

222 In the multivariate logistic regression models, having either *C. trachomatis* or *N. gonorrhoeae*
223 infection was associated with condomless anal intercourse in the prior month (aOR: 1.98; 95%
224 CI: 1.27-3.09) and sexualized drug use in the prior 6 months (aOR: 1.71; 95% CI: 1.09, 2.69).
225 (Table 3) Rectal and urethral symptoms in the prior week were associated with infections in
226 univariate analyses, but not in the multivariate model (aOR: 1.19; 95% CI: 0.73, 1.94). When
227 examining each infection separately, meeting sex partners in mobile apps in the prior 6 months
228 was an independent risk factor for *N. gonorrhoeae* infections (aOR: 2.32; 95% CI: 1.19, 4.53),
229 but not *C. trachomatis* (aOR: 0.83; 95% CI: 0.49, 1.43). Both condomless anal sex in the prior
230 month (aOR: 2.10; 95% CI: 1.27-3.45) and sexualized drug use in the prior 6 months (aOR: 2.20;
231 95% CI: 1.32-3.68) were associated with *C. trachomatis*, but not *N. gonorrhoeae*. There was no
232 evidence of multicollinearity among variables in the multivariate logistic regression.

233

234 **Discussion**

235 In this study including 529 primarily MSM in an HIV PrEP program in Hanoi, Vietnam, testing for
236 *C. trachomatis* and *N. gonorrhoeae* at multiple anatomic sites identified a high prevalence
237 (29%) of infections. Rectal infections were most common for *C. trachomatis* (14%), while
238 pharyngeal infections were most common for *N. gonorrhoeae* (11%), demonstrating the utility
239 of testing at multiple anatomic sites for the detection of infections outside of the genital tract.
240 While the prevalence of urethral and rectal *C. trachomatis* and *N. gonorrhoeae* infections were
241 higher among those who reported symptoms at those sites in the prior week, a majority of

242 overall infections (54%) were detected among those without symptoms, underscoring the
243 limitations of relying on syndromic management as an infection control strategy in this setting.
244 These findings highlight the opportunity to enhance STI diagnosis and treatment within HIV
245 PrEP programs in LMICs.
246
247 Our study provides important data on routine testing for *C. trachomatis* and *N. gonorrhoeae*
248 within a large HIV PrEP program in a LMIC setting, where prevalence data are limited. A recent
249 meta-analysis of STIs among people in HIV PrEP programs estimated a pooled prevalence of *C.*
250 *trachomatis* or *N. gonorrhoeae* was 24%, suggesting a slightly higher burden among
251 participants in our study population.[5] However, that study highlighted the scarcity of data
252 from LMICs, which makes comparisons difficult, but the study did not find a significant
253 difference in prevalence of chlamydia or gonorrhea by country income level. There is a paucity
254 of published prevalence estimates of *C. trachomatis* and *N. gonorrhoeae* among MSM on HIV
255 PrEP from other nearby countries in Asia, which could provide further context. One study done
256 among adolescent MSM and transgender women in Thailand found a *C. trachomatis* prevalence
257 of 15% and *N. gonorrhoeae* prevalence of 4.5%, estimates that are much lower than our study,
258 although pharyngeal testing was not performed in that study which would likely account for
259 some of that difference.[11] The prevalence of infections observed in our study align with
260 existing evidence from other, largely high-income, settings indicating a high burden of STIs
261 among MSM on HIV PrEP.[6,12]
262

263 Among participants in our study, we observed those reporting condomless anal sex were about
264 twice as likely to have *C. trachomatis* or *N. gonorrhoeae* infection and those having sexualized
265 drug use in the prior 6 months were 70% more likely to have *C. trachomatis* or *N. gonorrhoeae*
266 infection. Identifying factors associated with infections could help to focus testing among those
267 at highest risk for infections. For example, of the total 153 *C. trachomatis* or *N. gonorrhoeae*
268 infections in our study, testing those reporting either condomless anal sex or sexualized drug
269 use in the prior 6 months would have detected 75% of those infections. Meeting sex partners
270 on mobile apps is increasingly common globally and this behavior was associated with twice the
271 odds of *N. gonorrhoeae*, but not *C. trachomatis*, infections in our study, a finding that was also
272 observed in our previous work in a similar study population.[8] Possible explanations for this
273 observation might be there is a higher prevalence of *N. gonorrhoeae* among certain sexual
274 networks of online mobile app users or there is more oral sex within that network, since the
275 majority of these infections were pharyngeal. These findings indicate that focused testing for
276 *N. gonorrhoeae* among those meeting sex partners on apps could be a strategy to improve
277 gonorrhea control.
278
279 We found that reporting rectal or urethral symptoms in the prior week was not associated with
280 infections in multivariate analysis, highlighting the difficulty of using symptoms to identify
281 infections, given a high proportion of these types of infections are asymptomatic.[13] Despite
282 this, the prevalence of rectal and urethral *C. trachomatis* and *N. gonorrhoeae* was significantly
283 higher among those who reported symptoms in the prior week, suggesting symptoms are still
284 correlated with a higher frequency of infections at those sites. Our findings suggest that testing

285 for urethral infections among asymptomatic individuals is of limited value, as the prevalence in
286 this group was very low, 0.9% for *N. gonorrhoeae* and 3.1% for *C. trachomatis*; furthermore,
287 testing only at urethral sites would have missed more than three-quarters (77.8%) of these
288 infections. The low positivity coupled with the high costs of testing, approximately 25-32 USD
289 for one site *C. trachomatis/N. gonorrhoeae* testing in Vietnam, are important considerations,
290 especially as the costs are typically managed by the patient, outside of research settings.
291 Pooled testing, where samples from one individual from multiple anatomic sites are combined
292 into one sample for testing, is an approach that might be cost-saving but is associated with
293 some compromise in test sensitivity.[14,15] However, anatomic sites of infection are important
294 for treatment and follow-up, particularly with regard to antimicrobial resistance in *N.*
295 *gonorrhoeae*, which would limit the cost savings of this approach in a high prevalence setting
296 such as ours. Further research on the implementation and cost-effectiveness of pooled testing
297 within HIV PrEP programs in LMICs would help to provide further guidance.
298
299 Our study further highlights the high prevalence of *C. trachomatis* and *N. gonorrhoeae*
300 infections among people in HIV PrEP programs and the need to improve evidence-based
301 guidelines for testing, particularly in LMICs. Given the high prevalence and incidence of STIs in
302 HIV PrEP programs, many guidelines recommend quarterly screening for *C. trachomatis* and *N.*
303 *gonorrhoeae* among MSM on HIV PrEP.[16,17] Yet while some modeling studies support
304 quarterly screening to reduce the population prevalence, the clinical and public health evidence
305 supporting the frequency of testing is lacking and the populations coverage needed to achieve a
306 population-benefit of decreased prevalence is much higher than observed in practice.[18–22]

307 The recent Gonoscreen Study, a randomized-controlled trial evaluating quarterly screening for
308 *C. trachomatis* and *N. gonorrhoeae* compared to no screening among MSM in Belgium found
309 quarterly screening was associated with fewer *C. trachomatis* infections and complications, but
310 observed no difference among *N. gonorrhoeae* infections.[23] Additional research on
311 alternative screening frequencies, e.g. – every 6 months or annually, and in different settings
312 could provide further evidence on the public health benefits of different screening approaches.
313 Beyond the frequency of screening, there is also a larger debate about the utility of screening
314 for asymptomatic STIs in populations of MSM, particularly those on HIV PrEP.[24,25] While *C.*
315 *trachomatis* and *N. gonorrhoeae* infections increase the risk for HIV transmission and provide a
316 strong rationale for using these as an entry point for HIV PrEP,[26] the increased risk for HIV
317 acquisition caused by bacterial STIs is largely mitigated among those on HIV PrEP.[27,28]
318 Moreover, antimicrobial resistance is one potential consequence of increased screening and
319 treatment and is a significant concern, particularly for *N. gonorrhoeae* and *Mycoplasma*
320 *genitalium*; increased antibiotic consumption was observed among those randomized to
321 quarterly screening in the Gonoscreen study.[23] Antimicrobial resistance in *N. gonorrhoeae* is
322 particularly concerning in Vietnam, where the prevalence of ceftriaxone resistance, the first-line
323 agent for treatment, is more than 20% in some settings.[29]
324
325 Our study findings must be interpreted in light of the following limitations. First, the study
326 population might have been subject to selection bias. Efforts were made to expand inclusivity
327 by simplifying the study eligibility criteria to reflect that of the HIV PrEP program. Still, it was
328 not possible to recruit all PrEP program clients and 70% of those who were recruited agreed to

329 be screened; thus, it is possible those who chose not to participate were different than those
330 who participated. Second, our study outcome was the prevalence of *C. trachomatis* and *N.*
331 *gonorrhoeae* infections at each visit, so while participants were allowed to participate more
332 than once, few did, and we were unable to estimate the incidence of *C. trachomatis* or *N.*
333 *gonorrhoeae* infections. Third, our study population of primarily MSM were largely well-
334 educated, employed, and living in Hanoi, the second most populated city in Vietnam, and might
335 not be generalizable to other populations or settings. Our study took place within the largest
336 HIV PrEP program in Hanoi, which is a strength of our study.
337

338 **Conclusion**

339 Our findings provide further evidence of the high prevalence of *C. trachomatis* and *N.*
340 *gonorrhoeae* infections among people on HIV PrEP, including the high proportions of rectal,
341 pharyngeal, and asymptomatic infections. Despite the high prevalence of infections, the high
342 cost of molecular STI testing is a major barrier to implementing routine testing in HIV PrEP
343 programs in LMICs.[6] Testing for urethral *C. trachomatis* and *N. gonorrhoeae* infections among
344 those without urethral symptoms is likely to be of limited value, based on our findings. Further
345 research is needed to establish evidence-based recommendations on the role and frequency of
346 testing for asymptomatic infections, including the cost-effectiveness of different approaches.
347 Biomedical interventions like doxycycline prophylaxis and vaccinations are promising tools for
348 STI prevention and further research is needed on the effectiveness and implementation in LMIC
349 settings, where key factors such as antimicrobial resistance and differences in user preferences
350 will influence their impact.

Acknowledgements

The research was supported by a grant of no charge materials from Roche Molecular Systems and Abbott Molecular.

Authorship: PCA, HTB, GML, and JDK designed the study. PCA, GML, JDK obtained funding. HTB and LQP performed data management and data analyses. PCA wrote the first version of the manuscript. All authors reviewed, provided critical review, and approved the manuscript.

357 **References**

358 1 World Health Organization. Global progress report on HIV, viral hepatitis and sexually
359 transmitted infections, 2021. Geneva, Switzerland.: World Health Organization; 2021.
360 https://www.who.int/publications/i/item/9789240027077 (accessed 20 Jul2024).

361 2 Centers for Disease Control and Prevention. Sexually Transmitted Infections Surveillance
362 2022. Atlanta: US Department of Health and Human Services; 2024.
363 https://www.cdc.gov/std/statistics/2022/default.htm (accessed 12 May2024).

364 3 Kojima N, Davey DJ, Klausner JD. **Pre-exposure prophylaxis for HIV infection and new**
365 **sexually transmitted infections among men who have sex with men**. *AIDS* 2016; **30**:2251–
366 2252.

367 4 Traeger MW, Schroeder SE, Wright EJ, Hellard ME, Cornelisse VJ, Doyle JS, *et al.* **Effects of**
368 **Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection**
369 **on Sexual Risk Behavior in Men Who Have Sex With Men: A Systematic Review and Meta-**
370 **analysis**. *Clin Infect Dis* 2018; **67**:676–686.

371 5 Ong JJ, Baggaley RC, Wi TE, Tucker JD, Fu H, Smith MK, *et al.* **Global Epidemiologic**
372 **Characteristics of Sexually Transmitted Infections Among Individuals Using Preexposure**
373 **Prophylaxis for the Prevention of HIV Infection: A Systematic Review and Meta-analysis**.
374 *JAMA Netw Open* 2019; **2**:e1917134.

375 6 Ong JJ, Fu H, Baggaley RC, Wi TE, Tucker JD, Smith MK, *et al.* **Missed opportunities for**
376 **sexually transmitted infections testing for HIV pre-exposure prophylaxis users: a**
377 **systematic review**. *J Int AIDS Soc* 2021; **24**:e25673.

378 7 Wi TE, Ndowa FJ, Ferreyra C, Kelly-Cirino C, Taylor MM, Toskin I, *et al.* **Diagnosing sexually**
379 **transmitted infections in resource-constrained settings: challenges and ways forward**. *J*
380 *Int AIDS Soc* 2019; **22 Suppl 6**:e25343.

381 8 Adamson PC, Bhatia R, Tran KDC, Bui HTM, Vu D, Shiraishi RW, *et al.* **Prevalence, Anatomic**
382 **Distribution, and Correlates of Chlamydia trachomatis and Neisseria gonorrhoeae**
383 **Infections Among a Cohort of Men Who Have Sex With Men in Hanoi, Vietnam**. *Sex*
384 *Transm Dis* 2022; **49**:504–510.

385 9 Vietnam Authority for HIV Prevention and Control. Guideline on implementation HIV
386 preexposure prophylaxis (PrEP) services (Document No. 133). Vietnam Ministry of Health.;
387 2020.

388 10 Nevendorff L, Schroeder SE, Pedrana A, Bourne A, Stoové M. **Prevalence of sexualized drug**
389 **use and risk of HIV among sexually active MSM in East and South Asian countries:**
390 **systematic review and meta-analysis**. *Journal of the International AIDS Society* 2023;
391 **26**:e26054.

392 11 Songtaweesin WN, Pornpaisalsakul K, Kawichai S, Wacharachaisurapol N, Wongharn P,
393 Yodkitudomying C, *et al.* **Sexually transmitted infections incidence in young Thai men who**
394 **have sex with men and transgender women using HIV pre-exposure prophylaxis**. *Int J STD*
395 *AIDS* 2022; **33**:447–455.

396 12 World Health Organization. WHO implementation tool for pre-exposure prophylaxis (PrEP)
397 of HIV infection. Module 13. Integrating STI services. Geneva, Switzerland.: ; 2022.
398 https://www.who.int/publications/i/item/9789240057425 (accessed 11 Jun2024).

399 13 Kent CK, Chaw JK, Wong W, Liska S, Gibson S, Hubbard G, *et al.* **Prevalence of Rectal,**
400 **Urethral, and Pharyngeal Chlamydia and Gonorrhea Detected in 2 Clinical Settings among**
401 **Men Who Have Sex with Men: San Francisco, California, 2003**. *Clinical Infectious Diseases*
402 2005; **41**:67–74.

403 14 Aboud L, Xu Y, Chow EPF, Wi T, Baggaley R, Mello MB, *et al.* **Diagnostic accuracy of pooling**
404 **urine, anorectal, and oropharyngeal specimens for the detection of Chlamydia**
405 **trachomatis and Neisseria gonorrhoeae: a systematic review and meta-analysis**. *BMC Med*
406 2021; **19**:285.

407 15 Almeria J, Pham J, Paris KS, Heskett KM, Romyco I, Bristow CC. **Pooled 3-Anatomic-Site**
408 **Testing for Chlamydia trachomatis and Neisseria gonorrhoeae: A Systematic Review and**
409 **Meta-Analysis**. *Sexually Transmitted Diseases* 2021; **48**:e215.

410 16 Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of
411 HIV infection in the United States—2021 Update: a clinical practice guideline. ; 2021.
412 https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf (accessed 12
413 Jun2024).

414 17 British HIV Association, British Association of Sexual Health and HIV. BHIVA/BASHH
415 guidelines on the use of HIV pre-exposure prophylaxis (PrEP), 2018. ; 2018.
416 https://www.bhiva.org/PrEP-guidelines (accessed 12 Jun2024).

417 18 Jenness SM, Weiss KM, Goodreau SM, Gift T, Chesson H, Hoover KW, *et al.* **Incidence of**
418 **Gonorrhea and Chlamydia Following Human Immunodeficiency Virus Preexposure**
419 **Prophylaxis Among Men Who Have Sex With Men: A Modeling Study**. *Clinical Infectious*
420 *Diseases* 2017; **65**:712–718.

421 19 Reitsema M, Hoek AJ van, van der Loeff MS, Hoornenborg E, van Sighem A, Wallinga J, *et al.*
422 **Preexposure prophylaxis for men who have sex with men in the Netherlands: impact on**
423 **HIV and Neisseria gonorrhoeae transmission and cost-effectiveness**. *AIDS* 2020; **34**:621.

424 20 Hocking JS, Temple-Smith M, Guy R, Donovan B, Braat S, Law M, *et al.* **Population**
425 **effectiveness of opportunistic chlamydia testing in primary care in Australia: a cluster-**
426 **randomised controlled trial**. *The Lancet* 2018; **392**:1413–1422.

21 Tsoumanis A, Hens N, Kenyon CR. **Is Screening for Chlamydia and Gonorrhea in Men Who Have Sex With Men Associated With Reduction of the Prevalence of these Infections? A Systematic Review of Observational Studies**. *Sexually Transmitted Diseases* 2018; **45**:615.

22 Tao G, Patel CG, He L, Workowski K. **STI/HIV testing, STIs, and HIV PrEP use among men who have sex with men (MSM) and men who have sex with men and women (MSMW) in United States, 2019-2022**. *Clin Infect Dis* 2024; :ciae314.

23 Vanbaelen T, Tsoumanis A, Florence E, Van Dijck C, Huis in 't Veld D, Sauvage A-S, *et al.* **Effect of screening for *Neisseria gonorrhoeae* and *Chlamydia trachomatis* on incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gonoscreen study): results from a randomised, multicentre, controlled trial**. *The Lancet HIV* 2024; **11**:e233–e244.

24 Williams E, Williamson DA, Hocking JS. **Frequent screening for asymptomatic chlamydia and gonorrhoea infections in men who have sex with men: time to re-evaluate?** *The Lancet Infectious Diseases* 2023; **23**:e558–e566.

25 Ridpath AD, Chesson H, Marcus JL, Kirkcaldy RD, Torrone EA, Aral SO, *et al.* **Screening Peter to Save Paul: The Population-Level Effects of Screening Men Who Have Sex With Men for Gonorrhea and Chlamydia**. *Sexually Transmitted Diseases* 2018; **45**:623.

26 Kasaie P, Schumacher CM, Jennings JM, Berry SA, Tuddenham SA, Shah MS, *et al.* **Gonorrhoea and chlamydia diagnosis as an entry point for HIV pre-exposure prophylaxis: a modelling study**. *BMJ Open* 2019; **9**:e023453.

27 Volk JE, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S, *et al.* **No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting**. *Clin Infect Dis* 2015; **61**:1601–1603.

28 Hoornenborg E, Coyer L, Achterbergh RCA, Matser A, Schim van der Loeff MF, Boyd A, *et al.* **Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study**. *The Lancet HIV* 2019; **6**:e447–e455.

29 Adamson PC, Hieu VN, Nhung PH, Whiley DM, Chau TM. **Ceftriaxone resistance in Neisseria gonorrhoeae associated with the penA-60.001 allele in Hanoi, Viet Nam**. *The Lancet Infectious Diseases* 2024; **0**. doi:10.1016/S1473-3099(24)00230-5

Table 1. Baseline demographic, behavioral, and clinical characteristics of 529 participants enrolled from an HIV PrEP program clinic in Hanoi, Vietnam.

	Overall (N = 529)	**Positive for *C. trachomatis* (N=108)**		**Positive for *N. gonorrhoeae* (N=76)**		**Positive for *C. trachomatis* or *N. gonorrhoeae* (N=153)**	
	n (%)	**n (%)**	**p-value**	**n (%)**	**p-value**	**n (%)**	**p-value**
Median Age (IQR)	25.1 (21.7-29.5)	25.3 (21.1 – 29.7)	0.869†	24.8 (22.1 – 27.2)	0.281†	25.1 (21.5 – 28.3)	0.336†
Age group			0.644		0.243		0.834
16- 24 years old	261 (49.3)	51 (19.5)		38 (14.6)		75 (28.7)	
25- 34 years old	221 (41.8)	45 (20.4)		35 (15.8)		66 (29.9)	
35 - 63 years old	47 (8.9)	12 (25.5)		3 (6.4)		12 (25.5)	
Gender self-identification			0.126‡		0.316‡		0.232‡
Man	432 (81.7)	85 (19.6)		58 (13.4)		121 (28.0)	
Transgender woman	9 (1.7)	0		1 (11.1)		1 (11.1)	
Other/Unsure*	88 (16.6)	23 (26.1)		17 (19.3)		31 (35.2)	
Education			0.687		0.942		0.797
High school or below	52 (9.8)	13 (25.0)		8 (15.4)		17 (32.7)	
In post-secondary training	154 (29.1)	31 (20.1)		21 (13.6)		45 (29.2)	
Completed post-secondary training or higher	323 (61.1)	64 (19.8)		47 (14.6)		91 (28.2)	
Monthly income in million VND (median, IQR)	9.0 (5 – 15)	8.5 (5-14)	0.813†	8 (4.5 – 14.5)	0.566†	8 (5 – 14.5)	0.493†
Employed	419 (79.2)	84 (20.0)	0.682	63 (15.0)	0.392	123 (29.4)	0.668
Gender of sex partners prior 6 months			0.711‡		0.327‡		0.502‡
Men only	474 (89.6)	96 (20.3)		73 (15.4)		141 (29.7)	
Women only	13(2.5)	2 (15.4)		1 (7.7)		2 (15.4)	
Men and women	33 (6.2)	9 (27.3)		2 (6.0)		9 (27.3)	
No sex partners	9 (1.7)	1 (11.1)		0		1 (11.1)	
Number of sex partners in prior 1 month (n = 520)#	1 (1 – 2)	2 (1 – 3)	<0.001†	2 (1 – 2)	0.150†	2 (1 – 3)	<0.001†
Anal sex with male partners in prior 1 month (n = 447)#	396 (88.4)	95 (24.0)	0.043	64 (16.2)	0.219	131 (33.1)	0.043
Anal sex position with male partner (n = 396)#			0.633		0.109		0.385
Insertive anal sex always	137 (34.6)	29 (21.2)		22 (16.1)		44 (32.1)	
Receptive anal sex always	149 (37.6)	38 (25.5)		18 (12.1)		45 (30.2)	
Both insertive and receptive	110 (27.8)	28 (25.5)		24 (21.8)		42 (38.2)	
Condomless anal sex in prior 1 month (n = 396)#	203 (51.3)	63 (31.0)	0.001	39 (19.2)	0.091	83 (40.9)	0.001
Vaginal sex with female partners in prior month (n = 39)#	38 (7.2)	8 (21.1)	0.064	2 (5.3)	0.814	8 (21.1)	0.064
Deep kissing in prior week (n = 302)#	260 (86.1)	61 (23.5)	0.700	41 (15.8)	0.518	85 (32.7)	0.823
Any group sex, prior 6 months	65 (12.3)	13 (20.0)	0.929	14 (21.5)	0.078	22 (33.8)	0.350
Sexualized drug use with	235 (44.4)	67 (28.5)	<0.001	40 (17.0)	0.120	87 (37.0)	<0.001

	Overall (N = 529)	Positive for *C. trachomatis* (N=108)		Positive for *N. gonorrhoeae* (N=76)		Positive for *C. trachomatis* or *N. gonorrhoeae* (N=153)	
	n (%)	n (%)	p-value	n (%)	p-value	n (%)	p-value
poppers or erectile dysfunction medications, prior 6 months							
Any sexualized drug use, prior 6 months	239 (45.4)	68 (28.4)	<0.001	40 (16.7)	0.169	88 (36.8)	<0.001
Met sex partners via mobile apps, prior 6 months	297 (56.1)	66 (22.2)	0.244	55 (18.5)	0.002	97 (32.7)	0.032
Pharyngeal symptoms in prior week	126 (23.8)	21 (16.7)	0.232	20 (15.9)	0.581	33 (26.2)	0.438
Rectal symptoms in prior week	87 (16.5)	25 (28.7)	0.035	15 (17.2)	0.403	29 (33.3)	0.321
Genitourinary symptoms in prior week	72 (13.6)	17 (23.6)	0.469	15 (20.8)	0.092	26 (36.1)	0.148
Any genitourinary symptoms at the day of enrollment	14 (2.7)	7 (50.0)	0.012[‡]	8 (57.1)	<0.001[‡]	12 (85.7)	<0.001[‡]
Any symptoms in prior week	217 (41.0)	49 (22.6)	0.303	41 (18.9)	0.013	70 (32.3)	0.158
Self-reported STI diagnosis in the prior 3 months	29 (5.5)	6 (20.7)	0.970	6 (20.7)	0.318	9 (31.0)	0.796
Used antiseptic mouthwash in the previous month	286 (54.1)	65 (22.7)	0.152	38 (13.3)	0.442	84 (29.4)	0.805

Note: Column percentages shown for first column. Remaining values are shown as row percentages.

*Participants who were gender nonconforming or gender incongruent, or unsure of their gender identity.
[†]Wilcoxon rank-sum (Mann-Whitney) test was performed
[‡]Fisher's exact test was performed, Chi-Squared tests were performed otherwise
[§]Variables that contains missing values because "Don't know" or "Don't remember" choices were treated as missing.
[#]Sample size was lower than 529 due to skip pattern (e.g., sample size for "Condomless anal sex" was among people who reported engaging in anal sex)

Table 2. Prevalence of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* infections by anatomic site among 529 participants enrolled from an HIV PrEP program clinic in Hanoi, Vietnam.

Anatomic Site	**C. trachomatis (n/N*, %)**	**N. gonorrhoeae (n/N*, %)**	***C. trachomatis* or *N. gonorrhoeae* (n/N*, %)**	***C. trachomatis* and *N. gonorrhoeae* (n/N*, %)**
Total Infections (Any Site)	108 (20.4)	76 (14.4)	153 (28.9)	31 (5.9)
Single Site Infections				
Pharyngeal only	19/528 (3.6)	32/528 (6.1)	41/528 (7.7)	3/528 (0.6)
Rectal only	57/493 (11.6)	10/494 (2.0)	52/493 (10.6)	4/493 (0.8)
Urethral only	14/529 (2.7)	2/529 (0.4)	11/529 (2.1)	0/529 (0)
Multisite Infections				
Pharyngeal and rectal	9/493 (1.8)	18/494 (3.6)	26/494 (5.3)	13/493 (2.6)
Pharyngeal and urethral	1/528 (0.2)	5/528 (1.0)	7/528 (1.3)	3/528 (0.6)
Urethral and rectal	7/493 (1.4)	2/494 (0.4)	7/493 (1.4)	1/493 (0.2)
Pharyngeal, rectal, and urethral	1/493 (0.2)	7/494 (1.4)	9/494 (1.8)	7/493 (1.4)
Any pharyngeal	30/528 (5.7)	62/528 (11.7)	83/528 (15.7)	26/528 (4.9)
Any rectal	74/493 (15.0)	31/493 (6.3)	94/493 (19.1)	25/493 (5.1)
Any urethral	23/529 (4.3)	16/529 (3.0)	34/529 (6.4)	11/529 (2.1)

Table 3. Multivariable logistic regression with factors associated with *C. trachomatis* only, *N. gonorrhoeae* only, and *C. trachomatis* or *N. gonorrhoeae* infections.

	C. trachomatis		***N. gonorrhoeae***		***C. trachomatis* or *N. gonorrhoeae***	
Characteristics	aOR (95% CI)	p-value	aOR (95% CI)	p-value	aOR (95% CI)	p-value
Age group						
16 to < 25 years old	1.00		1.00		1.00	
25 to < 35 years old	0.75 (0.45, 1.27)	0.284	1.03 (0.58, 1.84)	0.912	0.81 (0.51, 1.30)	0.387
≥ 35 years old	1.27 (0.58, 2.80)	0.550	0.39 (0.11, 1.38)	0.144	0.76 (0.36, 1.64)	0.492
Two or more sex partners in prior 1 month	1.66 (0.97, 2.86)	0.066	1.16 (0.63, 2.14)	0.638	1.52 (0.94, 2.46)	0.086
Condomless anal sex in prior 1 month	**2.10 (1.27, 3.45)**	**0.004**	1.51 (0.86, 2.67)	0.152	**1.98 (1.27, 3.09)**	**0.002**
Sexualized drug use in prior 6 months	**2.20 (1.32, 3.68)**	**0.003**	1.09 (0.61, 1.94)	0.774	**1.71 (1.09, 2.69)**	**0.020**
Met sex partners via mobile apps	0.83 (0.49, 1.43)	0.513	**2.32 (1.19, 4.53)**	**0.013**	1.21 (0.74, 1.96)	0.445
Any anal or urethral symptoms in prior week	1.44 (0.84, 2.45)	0.185	1.30 (0.72, 2.36)	0.385	1.19 (0.73, 1.94)	0.491
Used an antiseptic mouthwash in the prior 1 month	1.15 (0.70, 1.87)	0.583	0.72 (0.41, 1.25)	0.240	0.85 (0.55, 1.32)	0.468
Model information						
Sample size included	396		396		396	
Hosmer-Lemeshow p-value	0.5244		0.5412		0.4685	
McFadden's R2	0.070		0.053		0.053	
Log likelihood	-202.98235		-165.80362		-237.93177	

Figure 1. Prevalence of *C. trachomatis* (Panel A) and *N. gonorrhoeae* (Panel B) infections at pharyngeal, rectal, and urethral sites, stratified by reported symptoms at that site in the prior week.

Footnote: *p-value ≤0.05; **p-value ≤0.01


A
C. trachomatis
Symptoms
No Symptoms
Positivity (%)
30
20
10
0
*
**
23.5
13.3
12.5
6.3
5.5
3.1
Pharyngeal
Rectal
Urethral
Anatomic site of infection


B
N. gonorrhoeae
Symptoms
No Symptoms
Positivity (%)
30
20
10
0
*
**
14.3
10.9
14.8
6.1
16.7
0.9
Pharyngeal
Rectal
Urethral
Anatomic site of infection